Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MGTX 
MeiraGTx Holdings PLC (MGTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: MGTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $27.33
1 Year Target Price $27.33
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -51.78% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 654.84M USD | Price to earnings Ratio - | 1Y Target Price 27.33 |
Price to earnings Ratio - | 1Y Target Price 27.33 | ||
Volume (30-day avg) 5 | Beta 1.34 | 52 Weeks Range 4.55 - 8.98 | Updated Date 10/15/2025 |
52 Weeks Range 4.55 - 8.98 | Updated Date 10/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.08 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1213.57% |
Management Effectiveness
Return on Assets (TTM) -42.42% | Return on Equity (TTM) -379.54% |
Valuation
Trailing PE - | Forward PE 1.61 | Enterprise Value 724061806 | Price to Sales(TTM) 17.27 |
Enterprise Value 724061806 | Price to Sales(TTM) 17.27 | ||
Enterprise Value to Revenue 19.1 | Enterprise Value to EBITDA -3.29 | Shares Outstanding 80447477 | Shares Floating 31742965 |
Shares Outstanding 80447477 | Shares Floating 31742965 | ||
Percent Insiders 20.03 | Percent Institutions 64.95 |
Upturn AI SWOT
MeiraGTx Holdings PLC
Company Overview
History and Background
MeiraGTx Holdings PLC, founded in 2015, is a gene therapy company focused on developing treatments for serious diseases. It has evolved through partnerships and acquisitions to broaden its therapeutic pipeline.
Core Business Areas
- Ophthalmology: Developing gene therapies for inherited retinal diseases (IRDs), including X-linked retinitis pigmentosa (XLRP) and achromatopsia.
- Salivary Gland Disease: Developing a gene therapy for radiation-induced xerostomia (salivary gland hypofunction) following cancer treatment.
- Neurodegenerative Diseases: Focusing on gene therapies for neurological diseases, including Parkinson's disease and amyotrophic lateral sclerosis (ALS).
- Other Gene Therapies: Developing a variety of gene therapies for other indications like diabetes.
Leadership and Structure
Alexandria Forbes, Ph.D., serves as President and Chief Executive Officer. The company has a board of directors and various management teams overseeing research, development, and operations.
Top Products and Market Share
Key Offerings
- AAV2-hRS1 (XLRP): A gene therapy candidate for X-linked retinitis pigmentosa (XLRP). Currently in clinical trials. Limited market share as it is not yet approved. Competitors include Biogen and other companies developing gene therapies for inherited retinal diseases.
- AAV-AQP1 (Radiation-Induced Xerostomia): A gene therapy candidate for radiation-induced xerostomia. Currently in clinical trials. Limited market share as it is not yet approved. There are a few other solutions on the market to treat radiation induced Xerostomia, but none are approved gene therapies
- AAV-GAD (Parkinson's Disease): A gene therapy candidate for Parkinson's disease. Competitors include companies developing alternative Parkinson's treatments, such as surgical interventions and drug therapies.
Market Dynamics
Industry Overview
The gene therapy industry is rapidly growing, with significant advancements in treating genetic diseases. There's increasing investment and regulatory support, but also challenges related to manufacturing, delivery, and cost.
Positioning
MeiraGTx is positioned as a clinical-stage gene therapy company focused on ophthalmology, salivary gland disease, and neurodegenerative diseases. Competitive advantage lies in novel gene therapy approaches and established partnerships.
Total Addressable Market (TAM)
The total addressable market for gene therapies is projected to reach billions of dollars. MeiraGTx is positioned within this market, particularly targeting specific indications with high unmet needs, and rare diseases.
Upturn SWOT Analysis
Strengths
- Strong pipeline of gene therapy candidates
- Focus on specific disease areas with unmet needs
- Experienced management team
- Strategic partnerships with leading institutions
Weaknesses
- Clinical stage company with no approved products
- High cash burn rate
- Reliance on clinical trial outcomes
- Small market capitalization compared to larger competitors
Opportunities
- Regulatory approval of lead candidates
- Expansion of pipeline through acquisitions or in-licensing
- Commercialization partnerships for approved products
- Advancements in gene therapy technology
Threats
- Clinical trial failures
- Competition from other gene therapy companies
- Regulatory hurdles and delays
- Manufacturing challenges and high costs
Competitors and Market Share
Key Competitors
- BIIB
- SPHR
- VRTX
Competitive Landscape
MeiraGTx competes with both large pharmaceutical companies and smaller biotech firms in the gene therapy space. Its advantage lies in specialized focus areas, but it faces challenges regarding financial resources and market access compared to larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical Growth is unavailable. Not included as per instructions, please use current financial data to provide the right analysis.
Future Projections: Future Projections are unavailable. Not included as per instructions, please use current financial data to provide the right analysis.
Recent Initiatives: Recent Initiatives include advancements in clinical trials for key gene therapy candidates and continued collaboration with industry partners.
Summary
MeiraGTx is a clinical-stage gene therapy company with a promising pipeline targeting specific disease areas. The company's success depends on the outcomes of its clinical trials and securing regulatory approvals. Financial stability and competition remain key challenges. Positive results in clinical trials would significantly improve the stock performance, while failure to achieve this can lead to it not being as successful.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MeiraGTx Holdings PLC
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2018-06-08 | CEO, President & Director Dr. Alexandria Forbes Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 386 | Website https://meiragtx.com |
Full time employees 386 | Website https://meiragtx.com | ||
MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase 2 trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.